

Global Cancer Conference & Medicare Summit

September 15-17, 2014 Hyderabad International Convention Centre, India

The impact of next generation sequencing technologies in clinical cancer research work and their application in cancer diagnostics and prognostics

Ashok Gopinath
Illumina, India

The rapidly evolving field of genomics and the giant strides being made in genomic technology are making significant impact to applied markets. The large volume of data on cancer genomes is increasing our knowledge base to try and interpret the causes and possibly reveal novel targets that could lead to the cure for this dreaded disease. Clinical research efforts have led to discoveries that are currently being leveraged to construct clinical diagnostics. Already the construction of clinically relevant biomarker panels (companion diagnostics) is promising to revolutionize the diagnostic and prognostic value for different therapeutic regimens. This talk will briefly address the current state of clinical genomics, more specifically cancer genomics and showcase Illumina's panel based clinical solutions and how they may be leveraged to try and provide clues to the directions clinical therapeutics will progress in.

Biography

Ashok Gopinath has a PhD from the Dept. of Biochemistry at the Indian Institute of Science (IISc) in Bangalore. He moved to Cornell University in Ithaca New York, for Postdoctoral research work in axon guidance. Since then, he re-committed himself to applied research work in the fundamental areas of diabetes and oncology in the industry most recently at Sanofi. He established many public private partnerships in the field of oncology and diabetes while at Sanofi. In Illumina now as the Head of Applied Genomics in India, he aspires to discover and impact evolving frontiers in healthcare and life sciences using genomics.

agopinath@illumina.com